A workshop was held on November [21][22] 1999 in Washington, D.e. to review and discuss current understanding of leprosy as a disease and My cobacterium leprae as the causative agent from the points of view of epidemiological, c1inical and basic research and, based on this review, to suggest areas of needed future research. This workshop was funded by the Heiser Program for Research in Leprosy and Tuberculosis and co-sponsored by the National Institute of Allergy and Infectious Diseases. Twenty-three scientists actively engaged in leprosy research, plus two additional individuaIs participating by teIephone conference call, contributed to the proceedings their knowledge pertaining to leprosy as an infectious di sease and M. leprae as the causative agent. A paneI of six scientists with backgrounds in epiderniology, immunology, cell biology, molecular bioIogy and genetics, dermatoIogy and pharmacology, but not working in basic or c1inical leprosy research, evaluated the presented and published information in regard to potential future research efforts that could aid in the further curtailment of this disease.
The research programme to better understand M. leprae pathogenesis, to develop better drug therapies and to identify and test potential vaccine compositions was aided by a series of discoveries made over a number of years. A pioneering discovery by C. Shepard was the ability to infect the mouse hind footpad with M. leprae, which because of the low temperature of the footpad, grows 100-to 1000-fold over a period of 4-9 months. This system provided an opportunity to screen M. leprae for drug susceptibility. The discovery by E. Storrs and W. Kirchheirner of the susceptibility of the nine-banded arrnadillo (Dasypus nomencinctus) to infection by M. leprae provided a means to obtain large quantities of M. leprae from the spleen and liver after an 18-24 month infection period. Most recently, nude (nu/nu) rnice have been used to obtain significant quantities of physiologicaIly active M. leprae for detailed genetic and physiological studies. ln these rnice, hind footpad infection yields 10 10 M. leprae in 9-12 months.
The WHO supported MDT programme was directed at the goal of reducing the prevalence of leprosy to less than 1/10,000 in endernic countries throughout the world. Toward this end, WHO recommended in 1997 an additional chemotherapeutic drug regime called ROM, which inc1udes the adrninistration of a single dose of antibiotics to individuaIs with PB leprosy with a single lesiono The single dose contains 600 mg rifampicin, 400 mg ofloxicin, and 100 mg rninacycline. ln 1999, the worldwide prevalence of leprosy still exceeds 1/10,000 individuaIs.
Global epidemiology
ln considering the epiderniology of M. leprae infection and leprosy as a disease, it is important to define the terrninology currently used by investigators in this field. Prevalence, which is equal to the number of registered cases globally or by country, is the product of the incidence of disease, which is equivalent to the number of new cases or number of detected new cases during a given interval, such as within a year, and the duration of the disease in years. It should be emphasized that the completeness of case detection and reporting varies from country to country, hence the registered case prevalence often under-represents true prevalence and new case detection underestimates true incidence. It should also be noted that individuaIs who have completed MDT or another drug treatment regimen and who are M. leprae slit-skin smear negative but nevertheless have debilitating disease, are not counted among the number of registered cases. Thus, prevalence numbers begin to equal incidence numbers when the mean duration of disease approximates 1 year. This fits quite well with the use of MDT for 6 months to cure individuais with PB leprosy and 12-24 months to cure those with MB leprosy.
Since the inception of MDT in 1982, there has been an 85% reduction in global prevalence of leprosy with the number of registered cases during the past 4 years or so, being less than 1,000,000. ln 1999, the number of registered cases was 795,000 for a global prevalence of 1.4 per 10,000 individuaIs, a number which is in excess of the WHO year 2000 goal for leprosy control (elirnination) of less than one registered case per 10,000 population. The current plateau in prevalence during the past several years is quite likely due to the fact that the number of new cases detected each year has remained relative1y static or, in fact, may be increasing slightly. Thus, the number of new cases detected was 550,000 in 1985 and 795,000 in 1999 (approximately equal to the global prevalence in 1999) .
Although the prevaIence of leprosy is well below 1/10,000 in the majority of countries, there are about 20 countries in which the prevalence is far in excess of this number, with lndia accounting for almost 80% of the registered cases globally and Brazil, Indonesia and Bangladesh having very significant numbers. It is thus of criticaI importance to maximize the effectiveness of identifying new cases in these high prevalence countries and enrolling these individuaIs in MDT programmes in a timely manner. ln evaluating the significance of these numbers and the desired goal of eliminating, if not eradicating, leprosy as an infectious disease, the paneI discussed a diversity of issues. ln considering infection, it is generally acknowledged that many more individuals are infected with M. leprae than ever develop the disease. Thus, the maj ority probably undergoes self-cure prior to any disease symptoms being detected. ln addition, some individuaIs who develop symptoms usually associated with the PB form of the disease also undergo self-cure even in the absence of MDT. The time between infection and the onset of disease symptoms has very rarely been documented within several months of birth in infants bom from mothers infected with M. leprae. Leprosy is actually rare before 3 years of age for infants bom into a family with another individual with c1inical disease. At the other extreme, the onset of symptoms after infection can be as long as 30 years, as evidenced by the development of symptoms in military personnel who had been exposed many years previously in a leprosy endemic area. Thus, with the time between infection and onset of disease varying from 3 to 30 years, it is evident that some of the new cases currently being identified may be due to infections that occurred years before the availability of effective MDT. Both the time for development of disease symptoms and the likelihood for development of overt disease depend on many factors, which inc1ude the route of infection, host genetic factors to be discussed below, malnutrition affecting the vitality of the immune system, and possible prior exposure to environmental mycobacteria. As with some other diseases, socioeconomic status is a significant factor. When the GNP per capita increases above $500, the incidence of leprosy decreases. An additional important risk factor is the presence of infected household contacts. Estimates range from 10% to as high as 75% of new cases occurring in such households. Thus, 25-90% of all new cases arise in individuaIs that must have acquired the infection by contact with an infected individual outside of the household. Although the nasal route of infection is likely, it would appear that exposure of any mucosal surface to M. leprae organisms and infection through skin lesions or punctures are deserving of consideration. ln terms of reservoirs, most consider that leprosy is uniquely a human disease. Even though the nine-banded armadillo in the central southem United States and Mexico is frequently infected or is at least seropositive for M. leprae, there appears to be a very low incidence of documented transmission of M. leprae from armadillos kept as pets to pet owners. Never the1ess, the nine-banded armadillo, which is restricted to North America, is not likeIy to be a significant reservoir for M. leprae. More meaningful questions are how did the nine-banded armadillo become infected with M. leprae and do they or how might they transmit it to each other? Given their insectivorous attributes and burrowing ability, one has to question whether M. leprae might be a soil microorganism, at least in semi-tropical parts of the world where soil temperatures might be maintained at 30-34°C, a temperature range known to be of criticaI importance for the metabolic activity and survivability of M. leprae in the laboratory. The inability to cultivate M. leprae in the laboratory has prec1uded an evaluation of such possibilities in the past, although the m�thods developed by Norman Pace (Science , 1997; 276: 734-740 ) to look at microbial ecosystem diversity by ribotyping and other methods might be amenable to identification of organisms with M. leprae-specific gene sequences in soil samples. ln considering these possibilities and issues, it appears that MDT may not be implemented soon enough after c1inical diagnosis of disease to prec1ude transmission of M. leprae to others. The issue of whether individuais without c1inicaI symptoms, or those with just the paucibacillary disease, exhibit infectiousness for others is unanswered. Thus, developing better diagnostic methods to identify individuais who are infected but not yet diseased, so that MDT could be initiated in a more timely manner is of paramount importance. Likewise, consideration of prophylactic drug therapy for family members in a household with disease might prove beneficial in eliminating new cases that occur in such households. ln spite of the reduced prevalence, the steady or even increasing case detection caused the paneI to be pessimistic about the capacity of MDT to reduce the prevalence of leprosy further in the global population, let alone to eradicate leprosy. Thus, continued research on many fronts is needed to acquire the information to improve upon MDT or seek altemative solutions to this global health problem.
Susceptibility
Although there are numerous factors that inftuence susceptibility to M. leprae infection or the likelihood that infection will lead to disease, there is evidence accruing that genetic factors may predispose individuaIs either to an increased likelihood of infection or inftuence their progression to overt disease. Thus, there is a highly significant association between the presence of the HLA-DR2 allele and leprosy in Asia and in Africa. There is also increasing evidence of leprosy susceptibility genes being present in certain families in India, although genetic loci associated with such susceptibility have yet to be identified. Recent linkage analysis data reveal a linkage between leprosy susceptibility and genetic markers on chromosome 10. This susceptibility to M. leprae is also shared with susceptibility to other infectious diseases. Although not adequately studied, there may be genetic differences that determine a relative propensity to the development of erythema nodosum leprososum (ENL) and other types of reactions associated with M. leprae infection. Results from the human genome project will contribute the framework upon which to base future studies to refin e our understanding of the contribution of genetic susceptibility alleles to M. leprae infection and development of disease.
Immunology
The disease manifestations of leprosy represent a spectrum of immunological responses that range from Th l to Th2 type (Th lffh2 paradigm) similar to leishmaniasis in the mouse. For this reason, studying M. leprae infection and causation of disease symptoms will contribute to better understanding of human immunology. M. leprae infects macrophages via mannose, CR I, CR3, and CR4 receptors and scavenger receptors. Whether M. leprae within the phagosome secretes antigens that traffic to the macrophage cytoplasm for c1ass I presentation and/or stimulates c1ass II presentation from within the endosome is as yet unknown. Recent studies of macrophage processing suggest that it is likely that uptake of M. leprae by these cells will lead to antigen presentation by both c1ass I and c1ass II pathways (A. Rodriguez et ai ., Na ture Cel! Biology, 1999; 6: 362-368). On the other hand, the findings of Rodriguez et aI . suggest that uptake of M. leprae by dendritic cells might lead these cells to present antigen via both class I and II pathways. Both CD4 + and CDS + T ee1ls isolated from leprosy patients respond to M. leprae antigens and these T eells may possess "10 or ex{3 reeeptors. T ee1ls have been shown to respond to 30 or so M. leprae antigens, but there is no information as to whether these antigens have the potential to induee proteetive immunity or eontribute to immune dysfunetion and disease progression. CDI antigen-presenting ee1ls are important for presentation of lipid and glyeolipid antigens and play an as yet undefined role in the prevention or progression of disease. M. leprae infeetion initially promotes produetion of IL-I2 and IL-IS, the former potentiating the development of a Th I response. ln TI or PB leprosy, IL-2, IFN-'Y and GM-CSF are produeed. Even though the Th I response refleeted by produetion of these eytokines is often referred to as proteetive and is assoeiated with a reasonable frequeney of eradieation of M. leprae infeetions, individuais expressing a Th I type immune response may still exhibit nerve involvement and disabling disease. ln LL leprosy, IL-4, -5 and -10 are produeed in abundanee with high antibody titres to many M. leprae antigens. The most striking immunologieal feature in LL leprosy is the M. leprae antigen-specifie anergy in eell-mediated immunity. ln tubereuloid leprosy, there is a eytotoxie lymphoeyte (CTL) response in whieh granules eontaining the antirnierobial protein granulysin are likely delivered by T ee1ls to ee1ls infeeted with M. leprae, thereby killing these eells. ln this regard, granulysin is seen in CD4 + T eells in tubereuloid but not in lepromatous leprosy. This implies that the presenee of granules and delivery of granulysin, whether by CD4 + or CDS + T eells, is of importanee in eontending with M. leprae infeetion. On the other hand, there are CTL-type T eells that are double-negative for CD4 + and CDS + that seerete IFN-'Y and are eytotoxie. 1t is unclear whether these double-negative T ee1ls have any effeet on M. leprae infeetions.
Pathogenesis
Nerve damage and the eonsequenees of nerve damage, and reaetions, set leprosy apart from other diseases. The irreversible motor and sensory impairments eaused by leprosy lead to inereasing seeondary impairments long after the disease proeess has been arrested. Inter ventions that prevent, reverse, or lirnit nerve impairment due to leprosy are of the greatest priority. Mueh headway is being made in the fu ndamental understanding of M. leprae-nerve eell interaetions.
Mononuclear phagoeytes ingest M. leprae via eomplement reeeptors (CRI and CR3 on monoeytes and CRI, CR3, and CR4 on maerophages) and fr agments of eomplement eomponent C3 fix to the baeterial surfaee. C3 binds seleetively to phenolie glyeolipid-l (PGL-I), a moleeule on the surfaee of M. leprae. Thus, eomplement reeeptors on maerophages, eomplement eomponent C3, and PGL-I eomprise a three-eomponent reeeptor-ligand-aeeeptor moleeule system for mediating phagoeytosis of M. leprae. ln addition to attaehing to and infeeting maerophages and a variety of non-phagoeytie eells sueh as striated muscle, M. leprae attaehes to and invades Sehwann eells, the glial ee1ls of the peripheral nervous system. M. leprae possesses a surfaee antigen that binds speeifieally to the G domain of the ex-2 ehain of larninin-2, whieh in tum binds to a larninin-2 receptor, ex-dystroglyean, on Sehwann ee1ls. These reeeptors mediate the entry of M. leprae into Sehwann ee1ls. ln LL leprosy, M. leprae proliferate extensively in Sehwann eells of peripheraI nerves, but whether M. leprae gene produets or metabolites or the ensuing immune responses eontribute to nerve damage within lesions is unknown. ln any event, M. leprae elicits TNF-Q' and IFN--y production, both of which are associated with a strong inftammatory response.
It is important to identify specific adhesins on the surface of M. leprae that participate in one or more steps in the binding, entry and/or growth of M. leprae in macrophages and Schwann cells. Some progress has been made in this respect with the identification of the histone-like proteins and PGL-l as key adhesins. The question of the possible expression by M. leprae of invasins and the means by which M. leprae might use signal transduction mechanisms to stimulate cells to which they attach to endocytose them are also deserving of study.
A finding of considerable clinical importance is that many individuaIs 2 or 3 years after initiation of MDT, and lacking detectable viable M. leprae, nevertheless present with significant progressive nerve damage and persistent neuritis. Whether this is due to dead bacteria or the attempt to clear dead bacteria or their components is not clear. Steroid therapy administered prior to the onset of significant nerve damage is effective in about 60% of patients to prevent these permanent disabling symptoms. Thus, other affordable immuno suppressants are currently being evaluated for improved performance in preventing disabling disease.
Immunologically mediated episodes of acute or subacute inftammation, known as 'reactions', may occur in any type of leprosy except in indeterminate leprosy and can result in deformity and disability. Most reactions belong to two main types, type II (ENL) and type I (reversal reactions). The former occurs in LL and occasionally in BL cases; the latter occurs throughout the borderline spectrum. Thalidomide has been used to treat ENL since the early 1960s, and recent studies of its mode of action have provided useful insights into the pathogenesis and immunology of reactions. Patients with active ENL have elevated serum leveIs of TNF-Q', and thalidomide treatment rapidly reduces these leveIs with improvement of clinical symptoms. Thalidomide also serves to inhibit monocyte activation and inhibit T-cell activation. Thus, present-day research focuses on identifying non-teratogenic thalidomide analogues for the alleviation and understanding of ENL. Cortocosteroids (prednisolone) are the mainstay of treatment for type I reversal reactions and apparently act by switching off the Th l response associated with reactions. ln important studies, it has been demonstrated that prednisolone had little effect on the initial cellular immune response and cytokine profiles, but, by day 28, significant decreases were found in IFN--y, IL-12, and iNOS in most patients with good clinical outcomes. These studies serve to better define the immunological basis of leprosy pathogenesis but also highlight the difficulty of modulating overactive immune responses.
Genomics and molecular biology
Sequencing of the M. leprae genome was initiated in 1991 and a fully sequenced and annotated genome became available in 2000. The M. leprae isolate sequenced carne from an armadillo-passaged strain provided by the National Institute of Medical Research, Mill Hill, London, UK. The M. leprae genome is circular and contains 3 ·3Mb compared with 4·4Mb for M. tuberculosis. The M. leprae genome possesses 1700 open reading frames, whereas M. tuberculosis has 4000 open reading frames. Thus, functional gene density is considerably lower in the M. leprae genome than it is in the M. tuberculosis genome. The M. leprae genome contains a great deal of non-coding or pseudogene sequences and it is surprising that this 'junk DNA' has been retained. Another obligate intracellular parasite, Rickettsia, also has pseudogenes in its genome, although the 10% pseudogene content reported is less than for M. leprae where c10se to one-half of the genome is composed of non-coding pseudogene sequences. AIso, there are fewer insertion sequences, but more repetitive DNA sequences (RLEP, REPLEP, and LEPREP) in the M. leprae genome than in the M. tuberculosis genome.
A comparison of coding sequences shows there are proteins that have 35-95% amino acid identity between M. leprae and M. tuberculosis or BCG. The latter observation probably explains why BCG vaccination is sometimes partially effective in preventing M. leprae infection.
There appear to be very few differences in M. leprae genomes from different strains and this genome sequence conservation has hampered studies on transmission of specific strains within communities or countries. Only a single polymorphism has been found among M. leprae strains and this is due to the presence of two copies of the repeti tive sequence RLEP linked to the polA gene leading to inversion of polA in some strains as opposed to others. (There are at least 30 copies of the RLEP sequence scattered throughout the M. leprae genome.) Hopefully, the availability of the complete sequence of the M. leprae genome will facilitate the discovery of additional polymorphisms that will facilitate epidemiological studies and enable tracing the chain of transmission of specific M. leprae strains in humans.
The constancy of the M. leprae genome and especially the maintenance of such an array of pseudogenes in the absence of any apparent benefit is most surprising. Quite possibly the exceedingly long generation time of 2 weeks or so and the ability to prosper in phagocytic cells designed to kill microorganisms by generation of free radicaIs and production of a diversity of antimicrobial compounds has selected for the inordinate ability of M. lepra e to repair any and all genetic damage that may arise spontaneously or due to any of these insults. Such conjectures can be tested by using microarray technology and other means to identify genes expressed by M. leprae within specific cell types and by defining those gene products that enable M. leprae to attach to, invade and survive in macrophages and Schwann cells.
Physiology and genetics
M. leprae frozen at -80°C and then thawed has greatly reduced viability when assayed for growth in mouse footpads and greatly reduced metabolic activity as measured by CO 2 generated from oxidation of radioactive palmitate, a quantitative assay for measuring subtle changes in metabolismo Whether physiologic impairments consequent to freezing are repaired once M. leprae enters an animal host remains to be determined. Even so, for studies of organisms maintained at 32-33°C, it seems preferable to use microorganisms freshly harvested from nude mice. ln humans and mice, M. leprae prefers the coo ler parts of the body, while being able to multiply systemically in the armadillo, whose body temperature is 33-34°C. ln accord with these observations, metabolic activity is markedly impaired by incubation of M. leprae at 37°C. Storage at 4°C has the least adverse effect on M. leprae physiologic activity measured at 32-33°C. Physiologically active M. leprae incubated under optimal physiologic conditions are able to take up and incorporate glucose, 6-phosphoglu conate, glycerol (into lipids), amino acids into proteins and purines (hypoxanthine and adenine) and pyrimidines (cytosines and thymidine) into nuc1eic acids. Pyrimidines are incorporated into nuc1eic acids less efficiently than purines. Inorganic phosphate is also incorporated into macromolecules. Palmitate, in addition to its oxidation, is very efficiently incorporated into PGL-l and PDIM (phthiocerol dimycocerosate) but acetate and pyruvate are incorporated into macro molecular constituents very inefficiently. Unlike Rickettsia, M. leprae is unable to take up phosphorylated nuc1eotides. On the other hand, M. leprae take up and incorporate nuc1eosides more efficiently than purine and pyrimidine bases. Enzyme assays on metabolically active M. leprae indicate a functional tricarboxylic acid (TCA) cyc1e and glycolysis via the Embden-Meyerhof and hexose monophosphate shunt pathways. Work to confirm and extend studies with armadilIo-derived M. leprae is in progress using nude mouse-derived bacteria.
ln terms of the very slow growth rate of M. leprae, there is some suggestion that it is defective in NADH metabolismo This defect, in combination with its content of only one copy of genes encoding ribosomal RNA, may contribute to a very long generation time. It is now possible to examine questions such as these by using M. leprae maintained under metabolicalIy active conditions. M. leprae ce1ls can be infected with bacteriophage AE129 engineered to express luciferase. The finding that luciferase activity in these phage-infected ce1ls can be inhibited by anti-Ieprosy drugs offers an opportunity to undertake new types of research. Efforts are in progress to introduce the green ftuorescence protein gene (gfp), which will facilitate rnicroscopic tracking of M. leprae in animal tissues or in celIs in culture. Analysis of the M. leprae genome may suggest reasons for the inability of M. leprae to grow axenicalIy and for its slow growth rate. The ability to introduce foreign DNA into M. leprae will alIow investigators to test directly a variety of hypotheses by complementing M. leprae genes or by supplementing M. leprae with genes from other mycobacteria. Such introduced genetic information could be on a phage genome to be incorporated into the chromosome or more likely to replicate on a phasrnid, cosrnid or plasrnid replicon within M. leprae cells. Thus, coupling new evolving gene transfer procedures with the array of data discernible from genornic ana1ysis should accelerate the rate of progress in understanding M. leprae growth, infection, pathogenesis and distribution.
The availability of the sequence of alI complete ORFs in the M. leprae genome, combined with the power of modem proteornics (two dimensional polyacrylarnide gel electrophoresis, selective ion monitoring and other forms of mass spectrometry) has resulted in the realistic expectation that the entire proteome will soon be defined. Already, specific cationic proteins involved in Schwann celI interaction and a modest complement (as compared to M. tuberculosis) of lipoproteins involved in Th 1 and Th2 immune responses have been defined.
Anti-Ieprosy drugs and drug resistance
With the commenced use of sulpha drugs for chemotherapy of bacterial diseases in the 1930s, a di -substituted sulphone (Prornin) was tried for treating leprosy in Carville, LA in 1941, with encouraging results. Prornin was relatively expensive and required intravenous adrninistra tion, so other sulphone drugs were tried during the 1940s, inc1uding oralIy adrninistered dapsone. Dapsone therapy was introduced in India, Nigeria and Brazil in the late 1940s and was shown to be very effective in treating leprosy in alI three countries. Since dapsone was at that time only useful for treating patients with leprosy, and since most of these patients were too poor to pay for drugs, there was effectively no market for it. Consequently, dapsone was available for govemmental use at a very low cost. ln this regard, dapsone is inexpensive (as cheap as aspirin), stable, and relatively non-toxic. Nonetheless, M. leprae infections with secondary and then primary dapsone resistance appeared leading WHO to adopt the MDT program in 1982. This programme was based on the premise that the use of three drugs (rifampicin, clofazamine and dapsone) would preclude the development of resistance to any one of the component drugs used in MDT. It should be noted that rifampicin was chosen as one of the three drugs because of its bacteriocidal effect on M. leprae, but also because it was no longer under patent protection thereby decreasing its cost. Clofazamine was also inexpensive. Thus, alI of the three drugs used in MDT as welI as the drugs for the ROM regime, are donated by drug manufacturers (especialIy Novartis) free of charge. The World Health Organization, Nipon Foundation and the lntemational Federation of Anti-Leprosy Associations distribute these drugs. There are new macrolide and fluoroquinolone drugs that are highly active against M. leprae but because of cost are seldom used to treat leprosy in Africa, Asia and South America. These new drugs are likely to enter the treatment regimen only if they become inexpensive or are proven effective after a very brief treatment regimen or if drug resistance causes one or more of the existing drugs in the MDT repertoire to become ineffective. ln this regard, it is known that rifampicin resistance can arise quite readily if used alone and ofloxocin-resistant M. tuberculosis has arisen in lndia. Dapsone resistance has long been known, but its mechanism has only recently been elucidated. ln this last regard, it is not known whether use of MDT during the past 18 years has altered the frequency of dapsone-resistant M. leprae.
The availability of methods for research with metabolicalIy active M. leprae along with the ability to use luciferase or other reporters should facilitate screening of new drugs for effectiveness in kilIing M. leprae. ln this regard, the HIV epidemic has stimulated efforts to discover and evaluate new drugs for the control of M. tuberculosis and of the M. avium complexo Some of these new drugs are retained in tissues quite welI and might be effective for short-term treatment regimens and in alIeviating some of the problems associated with M. leprae's neurotropic propensity and adverse sequelae that arise as a consequence. Although the inclusion of three drugs in the MDT programme is wise, it must be surrnised that at some time multiple drug resistance will arise, especialIy if the incidence of new cases does not decline. Multidrug resistance would pose a significant impediment to the eradication of leprosy.
With the sequence of the M. leprae genome, it now becomes possible to use specific oligonucleotides and PCR to recognize mutations for resistance to rifampicin, ofloxicin, dapsone, etc. The problem with such PCR methods is that they must be done in an institution with the technical capabilities for such assays. Nevertheless, such tests can be done with smalI sampIes of materiaIs sent to a central testing institution and this would likely be as efficient an approach to monitor drug resistance as taking biopsy material, inocuIating footpads of Ilude mice, recovering sufficient cells and using a phage infection luciferase activity to screen for drug resistance or sensitivity.
Diagnosis and diagnostic reagents
The diagnosis of leprosy is stilI largely based on clinical symptomology and occasionalIy skin biopsies to verify the presence of acid-fast bacilli. It has been desired for many years, however, that some diagnostic method be developed that would detect infection and the presence of multiplying M. leprae as soon as possible before clinical signs are apparent. When PGL-l was identified as a M. leprae-specific antigen, efforts were directed at using the presence of antibodies to this molecule as a test for occult infection. Such antibodies can be detected prior to the onset of clinical symptoms. Anti-PGL antibodies, which are largely IgM, are quite prevalent in LL or MB patients but are not prevalent in TI or PB patients. Thus the detection of PGL-l or antibodies to it became less attractive as an early diagnostic indicator.
Another immune reactivity test involves intradermal inoculation of an autoclaved extract of armadillo-derived M. leprae, the so-calIed leprornin test, and is read at 3 weeks. The leprornin test is not analogous to the tuberculin test, which is read as a DTH reaction to soluble M. tuberculosis PDP 48 h after injection, and has no value as a diagnostic test for subclinical leprosy. However, the leprornin test can be a prognosticator for the type of leprosy a person is likely to develop (i.e. borderline tuberculoid or tuberculoid if the test is positive and borderline lepromatous or lepromatous if the test is negative).
Two new approaches are being taken to develop improved skin test antigens. ln one such approach, armadillo-derived M. leprae are fractionated to generate a set of protein antigens associated with the celI walI in one case and from the cytoplasm in another. These protein preparations are purified to remove alI non-specific immunosuppressive lipoglycans and lipids and these procedures are done under GLP conditions to satisfy US Food and Drug Adrninistration requirements for an IND (Investigative New Drug) to conduct a phase IIII trial in a leprosy endernic area. As this research progresses, there will be an integration between M. leprae genornics and proteornics wherein 2D polyacrylarnide gel electrophoresis is being used to identify M. leprae proteins encoded by the 80 or so genes unique to M. leprae and not present in M. tuberculosis. (Of course, these M. leprae-specific genes will have to be first evaluated for their absence in a diversity of other mycobacterial species, including those from soil.) ln another approach, peptide antigens representing M. leprae-specific epitopes have been suggested by comparison of M. leprae genome sequences with those from other myco bacteria. Some of these peptides seem likely to be M. leprae-specific by detection of T celI responses to them in the blood of patients with leprosy, but not by T cells from individuaIs previously vaccinated with BCG or with tuberculosis. It is likely, however, that some of the epitopes on these peptides may be MHC-restricted and thus give rise to T celI responses in only some patients. Nevertheless, the evaluation of many such peptides should enable the preparation of a cocktail that would be recognizable by one or more T cell clones present in the blood of most patients with leprosy, provided they are capable of making a T cell response to leprosy antigens. Whether the diagnostic methods under test will reveal infection long before clinical symptoms are recognizable is unknown. If so, then MDT can be initiated sooner with an increasing likelihood that both the prevalence and incidence of leprosy can be further reduced.
Vaccines and vaccination
BCG vaccination in Malawi and India, at least in some studies, has resulted in a reduction in the incidence of leprosy. Now that the genetic relationship between the various BCG va c cine strains is known, the leprosy research community can evaluate the success or non-success of various BCG vaccination trials, whether in controlling tuberculosis or leprosy, with the particular properties of the BCG strain used as the vaccine in that particular trial. This information would be useful for both M. tuberculosis and M. leprae control efforts, since those desiring to develop a vaccine against M. tuberculosis are endeavouring to specifically attenuate M. tuberculosis and M. bovis and would hopefully choose parent strains that would have the potential for inducing cross-protective immunity against both M. tuberculosis and
M. leprae.
A prophylactic leprosy vaccine trail conducted in South India in the early 1990s, comparing four vaccines (BCG, BCG and killed M. leprae, and two cultivatable lndian mycobacterial strains, W and lCRC), yielded promising results. Although it was possible to assess the overall protective efficacy of the candidate vaccines against leprosy in the study population, the observed incidence rates of leprosy were not sufficiently high to ascertain the protective efficacy of the candidate vaccines against progressive and serious forms of leprosy. Protection observed with the lCRC vaccine and the combination vaccine (BCG and killed M. leprae) meets the requirement of public health utility. However, the killed M. leprae vaccine is unlikely to be available in the future, but the lCRC vaccine is readily available and might be considered for more widespread implementation.
With the prevalence of leprosy approaching 1/10,000, it would seem unlikely that a prophylactic vaccine would be highly cost-effective in preventing leprosy. Thus, the community pressure to vaccinate would not be sufficiently large, except maybe in localized highly endemic areas within countries with a high prevalence and incidence of leprosy. On the other hand, a vaccine that would prevent M. tuberculosis infection as well as M. leprae infection would likely enjoy a much higher use and thus generate a more satisfactory outcome. By comparative analysis of the M. leprae and M. tuberculosis genomes, it may be possible to identify antigens that are highly cross-reactive and which might generate a protective immune response, specifically a CTL, Th 1-dependent type of immunity. The induction of mucosal and systemic immune responses directed at relevant surface antigens of M. leprae and of M. tuberculosis might contribute significantly to decreasing the likelihood of infection, especially since M. tuberculosis is a respiratory pathogen and there is considerable favor for this idea as a means of transmission of M. leprae.
Basic and clinical leprosy research community
The perceived success in eradicating leprosy coupled to the increasing global concem for tuberculosis, which has been very much augmented by the HN epidemic and the develop ment of drug-resistant M. tuberculosis, have caused many mycobacterial researchers previously working on leprosy to switch to working on tuberculosis. Thus, the National Institutes of Health is currently funding two contracts to provide much-needed M. leprae research resources and five investigator-originated research projects on various aspects of leprosy and M. leprae biology. The WHO TDR spends less than 2% of its total budget on leprosy and most of this is concemed with managing the MDT programme. There has been a similar decline in the number of laboratories globally conducting basic research on leprosy and this situation is not conducive to generating the types of knowledge needed to contend with this dread disease and to effect its eradication. lt should be emphasized that the members of the small leprosy research community collaborate extensively with one another sharing clinical materiaIs, research reagents, and importantly, exchanging personnel, some of who receive training in research laboratories and then retum to clinical institutes. The Armauer Hansen Research lnstitute in Addis Ababa, Ethiopia; the Central JAMA lnstitute for Leprosy in Agra, lndia; the Aga Khan University in Karachi, Pakistan; the Leonard W ood Memorial Research Center in Cebu City, Philippines; the Oswaldo Cruz Foundation with laboratories in Rio de Janeiro, Brazil and the Anandaban Hospital in Kathmandu, Nepal, all located in countries with endernic disease, facilitate these ongoing research efforts. ln addition, there are central leprosy research laboratories in many countries throughout the world that can be tapped for intellectual as well as clinical and research resources. Increased funding for leprosy research is needed and will be efficiently used by the cadre of well-trained and highly comrnitted investigators currently working in this field.
Conclusions and recommendations
Based on the foregoing, the paneI reached the following conclusions and recommendations.
1. It makes econornic and human sense to eradicate leprosy as a global problem. This is an unobtainable goal with the current knowledge and tools and dependence entirely upon the use of multi pIe drug therapy as presently carried out. An intensification of a much better funded research enterprise on M. leprae and leprosy is therefore necessary. 2. Investigation of the epiderniology, natural history and transrnission of leprosy should be given the highest priority. These studies will require development of improved DNA reagents, diagnostic materiaIs and diagnostic tests suitable for use in endernic countries. The roles of animal, and even soil, reservoirs for M. leprae need to be deterrnined since such information is essential to develop a plan for control and possible eradication of leprosy. 3. The materiaIs and information required for modem molecular epiderniology and for M. leprae detection in potential reservoirs will likely soon be available from analysis of the M. leprae DNA genornic sequence. Further improvements of means for genetic manipulation of M. leprae coupled with studies of M. leprae under physiological conditions will allow identification of gene products required for pathogenicity. Identification of gene products expressed during infection will establish mechanisms for disease-associated pathogenesis and allow the development of better diagnostic reagents and vaccines. For these reasons, research on M. leprae genornics, molecular biology, genetics and physiology should have a high priority. 4. The continued availability of standardized, high-quality research materiaIs including, but not lirnited to, armadillo-and mouse footpad-derived M. leprae, purified and characterized cell constituents and proteins, both native and recombinant, antibodies and genetic constructs will be invaluable for fu ture research progresso 5. Research on tuberculosis and M. tuberculosis is often relevant to the understanding of leprosy and M. leprae. For this reason, research on leprosy should take guidance from tuberculosis research in attempting to confirm important hypotheses without being mere1y duplicative. This wiU be a more cost-effective approach and focus leprosy research on issues that are unique to the disease and to the causative pathogen. 6. Since multiple drug therapy can eliminate the infection in the individual, but has little or no effect on subsequent pathology associated with reactional states and progressive nerve damage leading to deforrnity, it is imperative that further research be conducted on the basic mechanisms of immunological reactions and nerve damage in leprosy to develop interven tions that prevent such damage in M. leprae infected individuaIs. Collaborations between leprosy researchers and neuroscientists should therefore be fostered. 7. The current means to study physiologically active M. leprae should enable evaluative screens of new drugs for effectiveness in leprosy control, especially those now being developed and tested for efficacy against M. tubercu/osis. These drugs anel/or drug combinations can then be evaluated in the mouse footpad model. 8. The ultimate goal of controlling and even eradicating leprosy is likely to be dependent on development of a safe efficacious vaccine that prevents infection, especially infection by both M. tubercu/osis and M. /eprae. Acquiring basic knowledge of the immune responses needed to confer protection and identifying the M. /eprae antigens that elicit these responses is a high priority. ln addition to a preventative vaccine, consideration should be given to the development and evaluation of a vaccine with therapeutic potential in treating patients with leprosy.
and Gail Jacobs of the Tuberculosis, Leprosy and Other Mycobacterial Diseases Program, National Institute of Allergy and Infectious Diseases, US National Institutes of Health in getting the workshop planned and conducted and in facilitating the preparation of this reporto
The authors, paneI members and NIH staff are deeply appreciative of the Heiser Program for Research in Leprosy and Tuberculosis for funding this workshop, which by its occurrence and this report, will hopefully stimulate much needed research to decrease, if not eliminate, leprosy.
